Participated · Series A · Jul 2020

Caps Medical develops a highly selective, minimally invasive non-thermal plasma device to treat solid tumors. The platform attacks cancer cells without damaging surrounding healthy tissue and aims to trigger an immune response to target additional tumor-specific cells. The technology was developed in The Technion’s Plasma Lab in collaboration with Rambam Health Care Campus and was translated into a product by a team led by Ilan Uchitel at MEDX Xelerator. Founded in 2018 by MEDX Xelerator and based in Netanya, Israel, the company has been supported by MEDX Xelerator, with Boston Scientific and MEDX Ventures Group as major shareholders in the incubator. The $3.5M Series A will enable Caps Medical to perform its first clinical trial and further develop its solid tumor treatment portfolio. The company expects that study results will contribute toward achieving regulatory clearance in the U.S.; Harel Gadot will serve as Executive Chairman of Caps Medical’s board.

Participated · Series D · Feb 2016

Regentis Biomaterials develops cartilage repair solutions, with offices in Princeton, New Jersey and Or Akiva, Israel. Its core product, GelrinC, is a proprietary hydrogel invented at the Technion that is implanted as a liquid and cured in‑situ to form a resorbable implant gradually replaced by regenerated cartilage. Earlier trials in Europe and Israel showed GelrinC provided patients relief from knee pain and improved function to return to normal activities. The company closed a $15M Series D led by Haisco Pharmaceutical Group and intends to use the proceeds to conduct a pivotal clinical trial of GelrinC in the United States aimed at obtaining FDA marketing approval. As part of the investment, Haisco will serve as GelrinC's exclusive distributor in China. Regentis is led by CEO Alastair Clemow, Ph.D., and counts Medica Partners, SCP Vitalife Partners, Generali Financial Holdings and Technion funds among its investors. Regentis Biomaterials develops GelrinC, a biodegradable implant intended to enhance growth of articular cartilage in damaged knee joints. The company is based in Or Akiva, Israel and Princeton, NJ and is led by CEO and President Dr. Alastair Clemow. GelrinC is currently an investigational device; prior pre-clinical studies demonstrated its ability to regrow cartilage. Regentis is conducting a multi-center pilot study in Europe and Israel to evaluate the safety and performance of GelrinC. The company intends to use the new funding to expand clinical efforts for the implant. GelrinC is not available for sale in the U.S., Europe or Israel while clinical evaluation is ongoing.

Participated · Series A · Jul 2015

Eximo Medical has developed Cathi™, a patented hybrid catheter connected to a compact pulsed 355nm UV laser system. The catheter’s tip combines laser ablation with a mechanical blunt blade to improve accuracy and enable precise crossing of vessel blockages regardless of lesion type or vessel size. The company says the technology has the potential to optimize safety and reduce the risk of vessel perforation. Its initial catheters are designed to offer solutions for different blockage pathologies during atherectomy procedures in patients with peripheral artery disease (PAD). Eximo plans first‑in‑human clinical trials in Europe and Israel in Q4 of this year to test performance in treating PAD. The product pipeline also includes solutions for lead extraction and, at a later stage, catheters for interventional gastrointestinal procedures. The article notes PAD is a multi‑billion dollar market affecting 8–12 million Americans, with around 122,000 PAD‑related amputations annually.

Participated · Equity · Sep 2014

Avraham Pharmaceuticals develops ladostigil, a multifunctional drug candidate licensed from Yissum and the Technion, currently in a Phase 2b clinical trial for mild cognitive impairment (MCI). The on-going Phase 2b trial is a three‑year, multicenter, randomized, double‑blind, placebo‑controlled study of 210 patients across 16 centers in Germany, Austria and Israel; interim results showed no safety issues and positive trends on MRI brain‑volume loss, immune markers and cognitive parameters. The company will use the newly invested capital to advance the Phase 2b study and continue enrollment and follow‑up. Management has begun discussions with potential licensing partners based on encouraging interim analyses; a further interim analysis and final readout are expected in 3Q15 and 3Q16 respectively. Financially, the company announced an additional $4.5 million investment in the current round and noted that Yissum and Integra Holdings will now hold 46% of Avraham’s shares. Founded in 2010 and based in Yavne, Israel, Avraham lists Yissum, Pontifax, Clal Biotechnology, Integra Holdings and the Technion Research and Development Foundation among its investors. Avraham Pharmaceuticals develops ladostigil, a multi‑functional drug candidate licensed from Yissum and the Technion and designed to target mild cognitive impairment (MCI) and early Alzheimer's disease. The company is conducting a 36‑month, multicentre, randomized, double‑blind, placebo‑controlled Phase II study; 150 of 200 patients have been recruited across 16 centers in Germany, Austria and Israel, with an interim analysis expected in the first half of 2014. Ladostigil has shown neuroprotective activity in preclinical models and was reported as safe and well tolerated in Phase I and Phase II clinical trials. The company will use newly raised capital to pursue advanced product development for ladostigil and to continue the ongoing Phase II program. Avraham was founded in 2010 and is based in Yavne, Israel. Investors and scientific advisors include Yissum, Pontifax, Clal Biotechnology Industries, Integra Holdings and the Technion Research and Development Foundation, and the founding scientists from the Hebrew University and the Technion serve as advisors. Avraham Pharmaceuticals is developing ladostigil, a novel cholinesterase and brain‑selective monoamine oxidase inhibitor being pursued for Alzheimer’s disease, mild cognitive impairment (MCI) and other neurodegenerative disorders. The company holds an exclusive license to ladostigil from Yissum and the Technion Research and Development Foundation. Ladostigil has been shown to be safe and well tolerated in Phase I and Phase II clinical trials and has potential symptomatic and disease‑modifying properties. Avraham is using new capital to advance two Phase II programs in parallel: an ongoing double‑blind, placebo‑controlled Phase II trial in Alzheimer’s disease conducted at 20 sites in five European countries, and a planned 36‑month, multi‑center randomized double‑blind placebo‑controlled study in MCI. The MCI study is expected to commence in the first quarter of 2012. The company emphasizes neuroprotective activity and potential to address behavioral and psychological symptoms as part of its development strategy.

Participated · Series C · Jul 2012

Correlsense develops application monitoring and performance management software, offering its SharePath product suite to give visibility into where and why application problems occur. SharePath covers multiple protocols, platforms and end-user technologies to support IT operations professionals. The company serves large customers in the financial, telecom and retail sectors. Correlsense was founded in 2005 and is led by CEO Ken Marshall, operating out of Framingham, MA. The company recently closed a $3M Series C funding round. It intends to use the capital to expand sales and technology partner channels and to enhance its sales and marketing teams. Correlsense provides business transaction management solutions centered on its flagship product, SharePath. SharePath is a Business Transaction Management (BTM) platform that monitors and tracks all transactions of an application in real-time. The platform supplies IT departments with the data needed to manage service level agreements, monitor performance, plan capacity, handle change management and implement chargebacks. The company raised $8M in a Series B financing led by Accel Partners, with participation from Vertex Venture Capital, eXceed Technology and ProSeed Ventures. The new financing will support growing Correlsense's customer base and further development of its distribution channels with partners in North America and Europe.